Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $15

Benzinga · 05/23 14:45
Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $40 to $15.